526 completed, 165 terminated, 82 recruiting, 71 active not recruiting. 975 Phase 2, 260 Phase 1, 9 Phase 3.
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia Zanubrutinib, Obinutuzumab, Sonrotoclax - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2026-12-31 | 2026-06-30 |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-05-12 |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 95 | 2026-12-01 | 2026-09-14 |
| A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLL Zanubrutinib, Sonrotoclax - CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | German CLL Study Group | 80 | 2026-12-01 | 2026-10-27 |
| Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2026-12-01 | 2026-10-29 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor Nemtabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 32 | 2026-11-08 | 2026-11-03 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-09 | 2026-10-08 |
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-10-01 | 2026-09-14 |
| Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 30 | 2026-10-01 | 2026-07-08 |
| Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Kerry Rogers | 155 | 2026-10-01 | 2026-08-31 |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-11-03 |
| Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). Pirtobrutinib, Fludarabine, Cyclophosphamide - CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | French Innovative Leukemia Organisation | 82 | 2026-09-01 | 2026-06-03 |
| Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors Discontinuing Bruton tyrosine kinase inhibitors (BTKi) therapy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 45 | 2026-09-01 | 2026-08-05 |
Showing 20 of 975. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (920) · Lymphoma, Non-Hodgkin (309) · Lymphoma, Follicular (295) · Leukemia (288) · Lymphoma, Mantle-Cell (269) · Lymphoma, B-Cell, Marginal Zone (261) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (250) · Lymphoma (247) · Lymphoma, Large B-Cell, Diffuse (238) · Hodgkin Disease (198) · Burkitt Lymphoma (172) · Leukemia, Myeloid, Acute (172) · Multiple Myeloma (157) · Lymphoma, Large-Cell, Immunoblastic (149) · Waldenstrom Macroglobulinemia (145)
Hemic and Lymphatic Diseases (975) · Neoplasms by Histologic Type (972) · Immune System Diseases (969) · Immunoproliferative Disorders (969) · Lymphatic Diseases (968) · Hematologic Diseases (959) · Lymphoproliferative Disorders (956) · Leukemia, Lymphoid (955) · Neoplasms (936) · Pathological Conditions, Signs and Symptoms (929) · Pathologic Processes (928) · Disease Attributes (927) · Chronic Disease (924) · Leukemia (687)
Cyclophosphamide (188) · Rituximab (186) · fludarabine phosphate (142) · fludarabine (85) · Mycophenolic Acid (80) · Peripheral Blood Stem Cell Transplantation (80) · venetoclax (67) · ibrutinib (64) · Tacrolimus (62) · Whole-Body Irradiation (62) · Lenalidomide (60) · Busulfan (52) · Cyclosporine (52) · obinutuzumab (52) · Filgrastim (51)
M.D. Anderson Cancer Center (80) · Fred Hutchinson Cancer Center (57) · National Cancer Institute (NCI) (47) · Mayo Clinic (26) · Memorial Sloan Kettering Cancer Center (22) · Masonic Cancer Center, University of Minnesota (19) · National Heart, Lung, and Blood Institute (NHLBI) (18) · City of Hope Medical Center (17) · German CLL Study Group (17) · Gilead Sciences (15) · H. Lee Moffitt Cancer Center and Research Institute (13) · Roswell Park Cancer Institute (13) · Alliance for Clinical Trials in Oncology (12) · TG Therapeutics, Inc. (10) · University of Nebraska (9)
United States (734) · China (67) · Italy (64) · Germany (56) · United Kingdom (51) · France (48) · Canada (44) · Spain (39) · Australia (34) · Poland (31) · Austria (24) · Belgium (22) · Israel (17) · Czechia (16) · South Korea (15)
Brenda Sandmaier (8) · Alessandra Ferrajoli, MD (7) · Thomas E. Witzig, MD (6) · David Maloney (5) · John Byrd (5) · Robert O. Dillman, MD, FACP (5) · Ajay Gopal (4) · Alessandra Ferrajoli (4) · Asad Bashey, MD, PhD (4)
PMID 32499241, PMID 34515338, PMID 34398557, PMID 23524640, PMID 29358183, PMID 23065508, PMID 26182309, PMID 34608724, PMID 41843779, PMID 19826119, PMID 22133778, PMID 22289993, PMID 23547837, PMID 23886836, PMID 24443277, PMID 24990615, PMID 26472751, PMID 26813675, PMID 27503501, PMID 27601462, PMID 28714866, PMID 29437592, PMID 31023700, PMID 31196847, PMID 31208944, PMID 32209572, PMID 33067379, PMID 36442911, PMID 37227160, PMID 38620092, PMID 40472301, PMID 42411504, PMID 42541678, PMID 10204198, PMID 12393429, PMID 12663715, PMID 1403051, PMID 14508361, PMID 14767498, PMID 15107815, PMID 15356646, PMID 15817673, PMID 15911237, PMID 16051743, PMID 16115130, PMID 16186597, PMID 16344317, PMID 16520464, PMID 16586495, PMID 16731764
P30CA015704 (26), P30CA015083 (20), U10CA031946 (11), P30CA033572 (10), P01CA018029 (9), P30CA016672 (9), 2023 (7), P30CA016058 (7), 2009 (6), 2015 (6), P01CA078902 (6), P30CA006973 (6), P30CA036727 (6), 2005 (5), 2016 (5)